SEC EDGARSEP 21 min read$OCUL

Notman Donald sold $11K of OCUL

Notman Donald (Chief Operating Officer) sold 1,099 shares of OCULAR THERAPEUTIX, INC (OCUL) at $10.24 on 2026-08-31.

Original reporting

SEC EDGAR · Notman Donald

Published Sep 2, 2026, 8:01 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 2, 2026, 8:31 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$OCUL

Neutral

high confidence

Mentioned

$OCUL

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$OCULNeutralLow

Why it matters

The transaction is unlikely to affect OCUL's price or investor sentiment.

Market read

Low relevance; typical insider sell with minimal market impact.

What to watch

Potential upcoming dilution or secondary offering not disclosed in this filing.

Relevance 3/10Novelty 4/10Timing: post-market filing

Background

Form 4 filings disclose insider trades; a $11K sale by the COO is routine.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$OCULNeutralHigh confidence

Context

Chief Operating Officer sold 1,099 shares for $11,254, reducing his stake to 366,529 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is small relative to float and disclosed via Form 4, a routine transaction.

Market effects

Sector

None; the transaction is company‑specific.

Regional

None; limited to OCUL shareholders.

Global

None

Counterpoint

What could challenge this read

If the executive anticipates near‑term weakness, the sell could hint at downside risk.

Key entities

person
Notman Donald
Chief Operating Officer of Ocular Therapeutix, Inc.

Read at source ← All news

OCT 20

$OCULMedAI 8/10

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win

Ocular Therapeutix (OCUL) plans to file for FDA approval of AXPAXLI in Q4, following positive SOL-1 trial results. The company discussed trial design and competitive developments, highlighting patient selection and trial design importance. OCUL has $600M in cash and expects runway into 2028. They are preparing for a potential AXPAXLI launch.

finance.yahoo.com2 min

OCT 20

$OCULHighAI 8/10

Ocular Therapeutix at chardan healthcare conference: wet amd push advances

Ocular Therapeutix (OCUL) presented at Chardan's conference, highlighting its wet AMD drug AXPAXLI. The company reported SOL-1 trial success, a clear FDA path, and $600M cash runway. Management emphasized AXPAXLI's maintenance-therapy model and competitive advantages. OCUL shares rose 4.13% to $6.55.

investing.com2 min

OCT 16

$OCULLow

Sanjay Nayak resigns as Chief Strategy Officer at Ocular Therapeutix

Ocular Therapeutix announced that Sanjay Nayak resigned as Chief Strategy Officer, effective October 16, 2026, to become CEO of a private company. No replacement was disclosed.

tradingview.com1 min

OCT 12

$OCULHigh

UBS initiates Ocular Therapeutix stock with buy rating on Axpaxli potential

UBS initiated coverage on Ocular Therapeutix (OCUL) with a buy rating and $14 price target, citing Axpaxli's potential in retinal therapy. The stock trades at $7.54, with UBS modeling $3.3B in 2035 sales. Positive Phase 3 trial results and regulatory updates are expected. Analysts remain optimistic despite competitor setbacks and delayed trial readouts.

investing.com2 min

SEP 28

$OCULHighAI 8/10

OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs

Ocular Therapeutix (OCUL) shares dropped 22% as competitors Kodiak Sciences (KOD) and 4D Molecular Therapeutics (FDMT) reported positive updates on their wet AMD treatments. KOD's DAYBREAK study met goals, while FDMT's 4D-150 showed lasting benefits. OCUL's AXPAXLI is in development, with FDA filing planned for late 2026.

tradingview.com2 min

SEP 25